{"id":"W2622613223","doi":"10.1200/jco.2017.35.15_suppl.1088","title":"Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Nausea; Cohort; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003588006,0.0002874944,0.002589001,0.0001262241,0.0002309331,0.00002994694,0.0009661635,0.0002726309,0.0005703062],"category_scores_gemma":[0.003147667,0.0001958406,0.0006051205,0.00009323787,0.0005805023,0.0003841242,0.0001749904,0.0007595991,0.000003752406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002028399,"about_ca_system_score_gemma":0.002321421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003056558,"about_ca_topic_score_gemma":0.0007726608,"domain_scores_codex":[0.9950902,0.0005503491,0.003011789,0.0004824385,0.0005662506,0.0002990101],"domain_scores_gemma":[0.9875296,0.004813535,0.005273392,0.001107539,0.0009725585,0.0003033235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6385007,0.02734478,0.02399877,0.0000399768,0.01067256,0.0004801747,0.0008399884,0.000006716316,0.0003782512,0.000002724268,0.00840528,0.2893301],"study_design_scores_gemma":[0.2063365,0.1430802,0.637198,0.0003497656,0.003199007,0.0002838441,0.001061743,0.0006055215,0.0004801135,0.0002683467,0.00692447,0.0002124715],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816197,0.001478835,0.0002675907,0.0113179,0.001818525,0.002043046,0.00121777,0.000007792348,0.000228912],"genre_scores_gemma":[0.9899946,0.005273102,0.001026521,0.001801996,0.001480402,0.00005679951,0.0000629019,0.00003866812,0.0002650339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6131992,"threshold_uncertainty_score":0.7986149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2259555002164314,"score_gpt":0.540515536048429,"score_spread":0.3145600358319975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}